Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 797 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Celgene Clear all
Terminated Phase 1 Interventional

A Study of the mTOR Inhibitor Rapamycin (Rapamune, Sirolimus) in Combination With Abraxane in Advanced Solid Cancers

NCT00337376
View directory record Official record
Conditions
Advanced Solid Cancers
Interventions
Rapamune, Abraxane
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 14, 2014 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Nab® -Paclitaxel (Abraxane®) Plus Gemcitabine in Subjects With Locally Advanced Pancreatic Cancer (LAPC)

NCT02301143
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
nab-Paclitaxel, Gemcitabine, Chemoradiation, Capecitabine, Surgery
Drug · Procedure
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 18, 2026, 9:37 AM EDT
Terminated No phase listed Observational

Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study

NCT04982471
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
Interventions
Not listed
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
53
States / cities
Hot Springs, Arkansas • Boulder, Colorado • Pensacola, Florida + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

NCT03803644
View directory record Official record
Conditions
Healthy Volunteer
Interventions
CC-92480
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2020 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma

NCT00426764
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Romidepsin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
45
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

NCT04373187
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 28, 2021 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01060384
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Lenalidomide, ofatumumab
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
2
States / cities
Grand Island, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

NCT02181218
View directory record Official record
Conditions
Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse
Interventions
Romidepsin, Gemcitabine, Oxaliplatin, Dexamethasone, Pegfilgrastim
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
Chicago, Illinois • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 18, 2026, 9:37 AM EDT
Withdrawn Phase 2 Interventional

Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation

NCT03881735
View directory record Official record
Conditions
Blasts Under 5 Percent of Peripheral Blood White Cells, Bone Marrow Blasts Decreased by 50 Percent or More Compared to Pretreatment Level, IDH2 Gene Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Enasidenib, Hematopoietic Cell Transplantation
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Buffalo, New York • East Hills, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of CC-5013 Monotherapy in Subjects With Myelodysplastic Syndromes

NCT00064974
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
CC-5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
38
States / cities
Scottsdale, Arizona • Tucson, Arizona • Berkeley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2013 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab

NCT02935790
View directory record Official record
Conditions
Malignant Melanoma
Interventions
ACY-241, nivolumab, ipilimumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 18, 2026, 9:37 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access for Marizomib

NCT04644107
View directory record Official record
Conditions
Solid Tumor
Interventions
Marizomib
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
U.S. locations
1
States / cities
Summit, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Azacitidine and CAPOX in Metastatic Colorectal Cancer

NCT01193517
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Azacitidine, Capecitabine, Oxaliplatin, Azacitidine MTD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2020 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

NCT01460940
View directory record Official record
Conditions
Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
Interventions
panobinostat, lenalidomide
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 18, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

NCT00281528
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
ABI-007 (Abraxane), bevacizumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fresno, California + 32 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2019 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

NCT02934269
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Placebo, CC-90006
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2018 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Not applicable Interventional

Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome

NCT00002157
View directory record Official record
Conditions
HIV Infections, HIV Wasting Syndrome
Interventions
Thalidomide
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Warren Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

NCT01519011
View directory record Official record
Conditions
Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
oral azacitidine
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
La Jolla, California • Denver, Colorado • Las Vegas, Nevada + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1 Interventional

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

NCT00840931
View directory record Official record
Conditions
Leukemia
Interventions
lenalidomide, bystander vaccine
Drug · Biological
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

NCT01323751
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Oct 18, 2026, 9:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction

NCT00790842
View directory record Official record
Conditions
Multiple Myeloma, Plasma Cell Neoplasm
Interventions
Lenalidomide, Dexamethasone, Anticoagulants
Drug
Lead sponsor
PrECOG, LLC.
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 18, 2026, 9:37 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)

NCT00675441
View directory record Official record
Conditions
Graft-versus-Host Disease
Interventions
Lenalidomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 11, 2013 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to Rituximab

NCT01123356
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Ofatumumab, Lenalidomide
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Charleston, South Carolina • Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 3, 2015 · Synced Oct 18, 2026, 9:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00536341
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
lenalidomide, Rituximab, Fludarabine
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Bethesda, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2017 · Synced Oct 18, 2026, 9:37 AM EDT